论文部分内容阅读
11月4日,美国食品和药物管理局(FDA)批准抗凝药拜瑞妥(通用名:利伐沙班)用于减少非瓣膜性房颤患者的卒中风险。美国FDA药物研究与评价中心称:“房颤能导致血栓形成,血栓随血流到达脑部可阻断血流并引起致残性卒中。这一批
On November 4, the U.S. Food and Drug Administration (FDA) approved the anticoagulant Xarelto ® (generic name: Rivaroxaban) to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. FDA drug research and evaluation center said: ”Atrial fibrillation can lead to thrombosis, blood clots with blood flow to reach the brain can block the blood flow and cause disabling stroke.